Signum Surgical is a Rosenman Founders Pledge company.


Signum Surgical is making a huge push in commercializing its BioHealx device. The Galway, Ireland-based company said it has raised about €3.6 million through two grant funding awards to get the anal fistula treatment device on the market.

The grants include €2.3 million from the European Union Horizon 2020 SME Instrument, and €1.3 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF).

The company said the funding will support Signum Surgical’s CE mark and 510(k) submission. In addition, the grants will help support the launch of a 12-month clinical study of the BioHealx technology to treat patients with anal fistula.

Read more at MD+DI Online